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Background: Papillary renal cell carcinoma (pRCC) is a mixed group of tumors that constitutes about 15-20% of all
renal cortical cancers. Strong enhancement on computerized tomography (CT) is a feature of clear cell, but not of
pRCC making the differentiation of papillary tumors from benign cysts a diagnostic problem in some cases.
Case presentation: We report here a case of a female patient with pRCC that was initially diagnosed as a benign
renal cyst. The patient is a 66 year old Caucasian female who initially presented with an ultrasound showing a
2.6 cm hypo-echoic lesion within the inferior pole of her left kidney. This was followed by a contrast enhanced
computerized tomography that suggested the hypo-echoic lesion to be a hyper-attenuating benign renal cyst.
Follow-up CT scan 4 months later demonstrated an increase in the size of the lesion to 3.2 cm with equivocal
enhancement. A dual energy computerized tomography (DECT) showed the lesion to be a solid mass suspicious for
renal cell carcinoma. A robotic partial nephrectomy revealed a papillary renal cell carcinoma with negative margins.
Conclusion: In this case report, we reviewed the literature on variations in enhancement of renal tumors and the
possible role of dual energy contract enhanced CT in differentiating papillary tumors with low enhancement from
benign kidney cystic lesions.
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Papillary renal cell carcinoma (pRCC) is the second most
common type of renal tumors accounting for 15-20% of
kidney cancer [1,2]. pRCC is divided into type I and type
II differentiated on the basis of cytological and architec-
tural features [3-5]. These tumors tend to show low en-
hancement on computerized tomography (CT) imaging
posing a diagnostic dilemma for the practicing physician.
We describe a case of papillary renal cell carcinoma that
was initially diagnosed on contrast enhanced CT as a be-
nign cyst, with the discussion of how dual energy CT
(DECT) scan could be helpful in making the right diag-
nosis in such situations.* Correspondence: salanee@siumed.edu
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A 66 year-old Caucasian female, with past medical
history significant for asthma, presented with an asymp-
tomatic 3.2 cm lesion within the inferior pole of the left
kidney. The patient had no family history of kidney can-
cer and there were no significant findings on examin-
ation. The lesion had been diagnosed a few months ago
on an abdominal ultrasound as a hypo echoic 2.6 circu-
lar abnormality. No significant vascularity was seen in
the lesion using doppler ultrasound. A follow-up contrast
enhanced CT showed the abnormality to have Hounsfield
attenuation units of 63. The attenuation increased to 70
units on the early arterial and delayed phases. A diagnosis
of a hyper-attenuating benign renal cyst was consequently
made. A follow-up CT scan showed an increase in the size
of the lesion to 3.2 cm within 4 months and to have
equivocal enhancement of about 10 Hounsfield units onThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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significant wall thickening, septations, or mural nodules
(Figure 1a). The patient then presented to our clinic for
further management. Fortunately, a DECT scanner was
recently installed at an affiliate hospital of the Southern
Illinois University School of Medicine (St John’s Hospital -
Springfield, IL), and the Radiology Department at St.
John’s Hospital had communicated to us the possible
benefit of DECT in renal tumors with equivocal enhance-
ment characteristics. A shared decision was made with the
patient to proceed with DECT imaging of the kidneys to
further characterize her renal lesion. DECT was performedFigure 1 Radiological imaging of the patient's kidney tumor (a)
(top): Unenhanced CT of kidney and tumor. (b) (bottom):
Enhanced CT of kidney and tumor.using Siemens 128 dual source dual energy computerized
tomography machine, and Siemens Syngo Via software
was used to process the images. Iodine was noticed inside
the lesion on DECT indicating tissue enhancement that is
associated with solid tumors (Figure 1b). Recommen-
dation was made to the patient for tumor removal and
surgery was done robotically with no complications. Intra-
operatively, the lesion was found to be a solid tumor
emanating from the lower pole of the left kidney (see
Additional file 1 for timeline).
Pathologic results
The final pathology demonstrated papillary renal cell
carcinoma type I, approximately 3 cm in size, confined
to the kidney with negative surgical margins (Figure 2).
Discussion
The incidence of RCC is rising worldwide, with RCC
currently accounting for almost 3% of solid malignant
tumors [6]. Obesity, and increasing utilization of im-
aging modalities are some of the factors contributing to
the increase in RCC incidence [7-9]. CT scan is now rec-
ognized as the gold standard for evaluating RCC because
it provides information about the tumor itself and its
extension to surrounding structures. Multiple previous
studies have attempted to differentiate clear cell carcin-
oma from other subtypes of the same disease using en-
hancement qualities, however, the only solid finding was
that strong enhancement is a unique finding for clear
cell RCC [10,11]. The diagnosis of papillary renal cell
carcinoma is specifically problematic on CT since pRCC
tend to enhance to a lesser extent than the normal renal
cortex, and could be confused with more benign kidney le-
sions such as in the case of the patient we present in this
report. The low vascularity of pRCC could be used to ex-
plain the low enhancement of these tumors making their
differentiation from benign kidney cysts problematic. In
fact, it was not unusual for pRCC to show no enhancement
on angiography, when that modality was used to diagnose
RCC before CT dominated the field. In addition, while
clear cell tumors are generally large and have areas of ne-
crosis, hemorrhage, and calcification, pRCC are generally
smaller and homogeneous adding to the difficulty of differ-
entiating them from fluid filled renal cysts.
Dual energy CT scan is a recent development in imaging
technology that could change the way we image and
follow-up on renal tumors [12]. DECT deals with many of
the drawbacks of the contrast enhanced multiphase CT
that we currently use to manage kidney tumors. DECT de-
creases the amount of radiation patients are exposed to due
to the decrease in number of phases needed for a renal CT
scan because it depends on one phase therefore omitting
the need for pre-contrast images [13-16]. Furthermore, re-
cent advances in DECT is allowing for synthesis of
Figure 2 Hematoxylin and Eosin staining of the tumor tissue showing characteristic histology of papillary renal cell carcinoma.
(inset: 100× magnification).
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spectral separation, which promises a more accurate meas-
urement of renal tumors enhancement [17-19]. DECT
works on simultaneous acquisition of two different energy
spectra, and thus can acquire accurate information about
tissue composition. DECT uses photoelectric energy emit-
ted when an incident photon causes an electron to be emit-
ted from atomic shells, an event common for elements
with high atomic number like Calcium and Iodine, to iden-
tify different compounds. Therefore, DECT is able to differ-
entiate between iodine and the surrounding soft tissue
based on the difference in photoelectric energy between
Iodine and the elements constituting human soft tissue
(oxygen, carbon, nitrogen, and hydrogen) [20].
Iodine-specific dual-energy images on DECT allow for
color coded display of the iodine particles inside renal
lesions. With these types of images, one can differentiate
a non-enhancing cyst from a solid-enhancing mass.
Cysts would appear without any iodine signal because
they are avascular, while solid vascular lesions demon-
strate iodine as it accumulates in the volume being
examined. The sensitivity of the technology for iodine
signal compensates for the low vascularity of lesions like
pRCC, and allow for their accurate characterization as
solid masses [14,15,21-23]. Not only does DECT serve to
differentiate renal cysts from solid masses in everyday
patients, but it is also proving useful in special cases like
patients with polycystic kidney disease (PCKD). In such
patients, detecting solid growth enhancement in the
kidney parenchyma that is replaced by a large number of
cysts is very challenging. However, recent studies indicate
that DECT can also be useful in detecting such growth inPCKD with reduced radiation dose; a reduction that is
important considering that PCKD patients require serial
imaging for follow-up for extended periods of time [24].
Along the same lines, DECT is beneficial in detecting
residual cancer after thermal ablation of renal tumors.
Changes, due to ablation and perinephric bleeding, may
make it difficult to assess enhancement after ablative
procedure, where enhancement is the sign of viable
cancer. With iodine-specific dual-energy images, DECT
could be a valuable technology in the urologist armament-
arium to decide on the success of their therapeutic inter-
vention. Park et al. in a recent paper, presented 47 patients
treated with radiofrequency ablation (RFA) of renal tumor
followed by DECT to predict tumor progression at RFA
site, and he showed excellent diagnostic performance of
DECT (sensitivity 100% and specificity 91.5%) for pre-
dicting local tumor progression. He then concluded that
DECT allowed acceptable diagnostic performance after
RFA with decreased patient radiation exposure.
Magnetic resonance imaging (MRI) and renal ultra-
sound are two other modalities routinely used in differ-
entiating cystic from solid renal lesions. However, in
comparison to MRI, DECT has a shorter acquisition time,
is cheaper, and can be used in patients with pacemakers
and other contraindications for MRI. DECT is also super-
ior to ultrasound in that it is less operator dependent, and
provides better tissue characterization.
Finally, there is a growing body of research that aims at
using DECT to differentiate RCC subtypes, and to observe
response to targeted therapy in metastatic RCC. These
applications are based on using Iodine as a biomarker that
provides additional information on tumor texture and helps
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tyrosine kinase therapy [13,25].
Conclusion
DECT, if validated in clinical practice, could save pa-
tients multiple testing to differentiate between benign
renal lesions and solid masses with low enhancement
that could be aggressive and deadly. Future applications
of this technology beyond diagnosis are being developed,
and may greatly enhance the value in DECT as an imaging
tool in managing patients with renal tumors.
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